Summary
- Profile Type
- Business Offer
- POD Reference
- BOHR20250416003
- Term of Validity
- 22 April 2025 - 22 April 2026
- Company's Country
- Croatia
- Type of partnership
- Supplier agreement
- Commercial agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Croatian AI-driven bioinformatics company develops specialized software applications designed to automate complex omics data analysis. By integrating advanced artificial intelligence algorithms, their solutions deliver accurate, efficient, and time-saving bioinformatics services. The company is currently seeking partnerships with biotech companies, research institutions, and healthcare organizations interested in incorporating cutting-edge bioinformatics tools into their workflows.
- Full Description
-
A Croatian AI-driven bioinformatics company offers advanced software applications for automated omics data analysis. Its mission is to bridge the gap between cutting-edge bioinformatics and user accessibility by leveraging artificial intelligence to streamline complex workflows in genomics, transcriptomics, and other omics-related fields.
Founded by a multidisciplinary team with expertise in molecular genetics, bioinformatics, artificial intelligence (machine learning), and software engineering, the company was established in response to a significant challenge in the field: most existing bioinformatics tools demand advanced technical knowledge, manual parameter tuning, and substantial computing resources. These requirements often pose a barrier for researchers and biotech companies without dedicated data analysis teams.
To address this, the company has developed an AI-powered bioinformatics platform that automates data processing and minimizes the need for specialized programming or statistical skills. The platform incorporates large language models (LLMs) to offer an intuitive, natural language interface, enabling users to interact with the software and receive automated insights effortlessly.
This technology is particularly valuable for R&D institutions, biotech companies, and universities engaged in genomics, precision medicine, drug discovery, and related disciplines. The company offers:
• Ready-to-deploy AI-driven bioinformatics tools customizable to specific research needs;
• Integration services to embed its AI models into existing workflow systems;
• Technical support and consulting to optimize data analysis processes;
• Partnership opportunities for organizations seeking to strengthen their bioinformatics capabilities
By addressing key limitations of conventional bioinformatics software, the company’s AI-driven solutions meet the growing demand for user-friendly, automated tools. Their implementation helps organizations enhance data analysis performance, improve research efficiency, and accelerate scientific discoveries—while reducing the technical burden on internal teams. - Advantages and Innovations
-
The company's AI-powdered bioinformatics platform is specifically designed to simplify omics data analysis by addressing the core challenges faced by researchers and biotech companies. Unlike traditional solutions that demand extensive technical expertise, manual parameter adjustments, and substantial computational resources, this platform automates complex workflows – making bioinformatics more accessible, efficient, and user- friendly.
Key Innovations that our software offers:
• AI-Driven Automation – Our platform eliminates the need for manual data preprocessing, parameter selection, and result interpretation by leveraging machine learning and large language models (LLMs);
• Natural Language Interface – Researchers can interact with the software using intuitive prompts instead of complex scripts, making advanced bioinformatics tools available to a wider audience;
• Scalable SaaS Model – Users can access the platform on demand, reducing costs and infrastructure requirements compared to traditional bioinformatics solutions;
• Interdisciplinary Integration – Our system bridges the gap between AI, bioinformatics, and cloud computing, ensuring seamless workflow automation without compromising accuracy or flexibility, which is especially important in science and research;
• Reduced Time-to-Insights – By automating data processing and analysis, our solution significantly shortens research timelines, enabling faster hypothesis testing and decision-making. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Not relevant
- IPR status
- Secret know-how
Partner Sought
- Expected Role of a Partner
-
Preferred Partner Profile:
• Biotech Companies & Research Institutions – Organizations seeking to implement our AI-driven bioinformatics platform for genomics, transcriptomics, proteomics or any related field;
• Software & AI Development Firms – Companies interested in utilizing our advanced bioinformatics solutions to enhance their existing products or services;
• Hospitals & Clinical Research Centers – Healthcare institutions looking to incorporate bioinformatics tools for personalized medicine, diagnostics, or biomarker discovery;
Engagement Opportunities:
• Solution Implementation – Direct adoption of our bioinformatics platform with customization for specific research or clinical needs;
• Pilot Testing & Feedback – Collaborative testing with real datasets to demonstrate value and optimize performance for specific use cases;
• Strategic Partnerships – Long-term relationships with organizations looking to integrate advanced bioinformatics capabilities into their core operations;
• Distribution Agreements – Partners who can represent our technology in specific geographic markets or industry verticals.
The company offers flexible engagement models including subscription-based access, customized implementation services, and technology licensing options to meet diverse organizational needs. - Type and Size of Partner
- SME <=10
- R&D Institution
- University
- SME 11-49
- SME 50 - 249
- Type of partnership
- Supplier agreement
- Commercial agreement
Dissemination
- Technology keywords
- 01003003 - Artificial Intelligence (AI)
- 06003002 - Gene Expression, Proteome Research
- 06003001 - Bioinformatics
- 01003020 - Building Automation Software
- Market keywords
- 02007016 - Artificial intelligence related software
- 04015 - Gene Expression, Proteome Research
- 02007001 - Systems software
- 04014 - Bioinformatics
- Targeted countries
- All countries